GUT MICROBIOME AND GASTROINTESTINAL DYSFUNCTION IN PEOPLE WITH AUTISM
Vic Lin, Final Year PhD Candidate,
Gut-Brain Axis Laboratory, RMIT University
Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | September 2026
Vic Lin is a final-year PhD student in the Gut-Brain Axis Laboratory at RMIT University in Melbourne, Australia. His research focuses on understanding the gastrointestinal dysfunction commonly experienced by people with autism and exploring the connection between the gut microbiome and gastrointestinal function.
Vic completed his bachelor’s degree with honours at the Florey Institute of Neuroscience and Mental Health before starting his PhD at RMIT University.
His PhD investigates how metabolites produced by the gut microbiome may influence gastrointestinal physiology in autism. Using a mouse model of autism, Vic examines key aspects of gut function, including intestinal permeability and gut motility, and investigates whether these changes can be improved using a treatment designed to target potentially harmful microbial metabolites.
His research has been presented at conferences across Australia, including the Australasian Neurogastroenterology and Motility Association and the Australasian Society for Autonomic Neuroscience in 2025.
Through his work, Vic aims to further the understanding of the gut-microbiome connection in autism and contribute to the development of novel therapeutic strategies for gastrointestinal dysfunction to improve outcomes for people with autism.
Source: Supplied
https://orcid.org/0009-0008-1263-7339
-
Development of novel analytical and diagnostic tools using nanotechnology and microfluidics
Dr Alain Wuethrich is an NHMRC Emerging Leader fellow and ARC DECRA awardee at the Australian Institute for Bioengineering and Nanotechnology.
Hailing from Switzerland, research focuses on the development of novel analytical and diagnostic tools that harness nanotechnology and microfluidics; two rapidly growing fields with high potential to provide diagnostic solutions needed for precision medicine.
-
Dr Zarina Greenberg
RESEARCH IN SANFILIPPO
@ SAHMRI
ADELAIDE, SOUTH AUSTRALIA, AUSTRALIA -
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
